Beta-Adrenergic–Antagonist Drugs in the Prevention of Gastrointestinal Bleeding in Patients with Cirrhosis and Esophageal Varices
New England Journal of MedicinePublished 30 May 1991
Thierry Poynard, Paul Calès, Linda Pasta, G. Idéo, J P Pascal, L. Pagliaro
Citations495
SJR quartileQ1
SJR score19.08
SNIP13.47
Generate an AI Snapshot to get a quick, structured summary of this paper.
Study Snapshot
ObjectiveStudy objective
MethodsResearch methodology
PopulationPopulation studied
Sample sizeSample sizes
OutcomesStudy outcomes here
ResultsStudy results comes here
LimitationsResearch study limitations comes here
A concise AI-generated summary of the paper will appear here once you click Generate AI Snapshot.
TL;DR
Propranolol and nadolol are effective in preventing first bleeding and reducing the mortality rate associated with gastrointestinal bleeding in patients with cirrhosis, regardless of severity.
Abstract
Propranolol and nadolol are effective in preventing first bleeding and reducing the mortality rate associated with gastrointestinal bleeding in patients with cirrhosis, regardless of severity.
Keywords
Medicine
The LancetPROPRANOLOL—A MEDICAL TREATMENT FOR PORTAL HYPERTENSION?
326 Citations1980Didier Lebrec, Michèle Corbic +2 more
Continuous, oral administration of propranolol at doses which reduced the heart-rate by 25% produced a sustained decrease in portal venous pressure in cirrhotic patients with portal hypertension, which might be useful in preventing recurrent bleeding due to ruptured oesophageal varices.
New England Journal of MedicinePropranolol in the Prevention of First Upper Gastrointestinal Tract Hemorrhage in Patients with Cirrhosis of the Liver and Esophageal Varices
302 Citations1987Jean‐Pierre Pascal, Paul Calès
It is concluded that propranolol can decrease the incidence of first bleeding and death during a period of two years in patients with cirrhosis and large varices.
HepatologyThe Effect of Propranolol on Portal Hypertension in Patients With Cirrhosis: A Hemodynamic Study
275 Citations1982Didier Lebrec, Patrick Hillon +4 more
It is concluded that continuous oral administration of propranolol produced sustained reduction in portal venous pressure in patients with alcoholic cirrhosis.
The LancetMeta-analysis of value of propranolol in prevention of variceal haemorrhage
246 Citations1990Peter Hayes, IAD. Bouchier +2 more
The results seem to indicate the value of beta-adrenoreceptor blocking drugs for the primary prevention of haemorrhage from large oesophageal varices, however, there is still a need for large multicentre trials of Beta-blockade forPrimary prevention of variceal bleeding in patients without large varices and of comparisons between beta-blocker therapy with other treatments in secondary prevention.
HepatologyNadolol can prevent the first gastrointestinal bleeding in cirrhotics: A prospective, randomized study†
161 Citations1988G. Idéo, G. Bellati +2 more
A prospective, randomized trial to see whether β‐blockers could also prevent the first hemorrhage in patients who survived episodes of variceal rupture.
Journal of HepatologyNadolol for prophylaxis of gastrointestinal bleeding in patients with cirrhosis
142 Citations1988Didier Lebrec, Thierry Poynard +7 more
Although there was no overall significant effect of nadolol on the risk of bleeding in cirrhotic patients in good condition with large oesophageal varices, this study suggests that nadolinol reduced the riskof bleeding in compliant patients.
GutComparison of three adrenoreceptor blocking agents in patients with cirrhosis and portal hypertension.
111 Citations1984Peter R. Mills, A P Rae +4 more
Propranolol and prazosin have proved to be effective agents for the reduction of portal venous pressure.
HepatologyPropranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis: A prospective study of factors associated with rebleeding
99 Citations1987Thierry Poynard, Didier Lebrec +8 more
This study confirms the results of a previous randomized trial and suggests that certain factors play a role in the mechanism of rebleeding in patients receiving propranolol.
Journal of HepatologyPropranolol prevents first gastrointestinal bleeding in non-ascitic cirrhotic patients
66 Citations1989The Italian Multicenter Project for Propranolol in Prevention of Bleeding∗
A retrospective analysis according to the presence of ascites at randomization showed that in the subset without ascites the proportion of patients free of bleeding was significantly higher in the propranolol group than in the control group, and this difference was even more evident in the ascites-free period.
American Heart JournalEffects of nadolol treatment on renal and hepatic hemodynamics and function in cirrhotic patients with portal hypertension
39 Citations1984Angelo Gatta, David Sacerdoti +4 more
Nadolol seems to have properties useful for the treatment of portal hypertension in patients with liver cirrhosis, and the percentage of cardiac output distributed to the kidneys was significantly increased after nadlol treatment.